Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Toze, C. L.
Right arrow Articles by Barnett, M. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Toze, C. L.
Right arrow Articles by Barnett, M. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 11:S59-S61, 2000
© 2000 European Society for Medical Oncology

Symposium Articles

Allografting for indolent lymphoid neoplasms

C. L. Toze, J. D. Shepherd, J. M. Connors, N. J. Voss, R. D. Gascoyne, D. E. Hogge, H. G. Klingemann, S. H. Nantel, T. J. Nevill, G. L. Phillips, D. E. Reece, H. J. Sutherland, E. A. Conneally and M. J. Barnett

Division of Hematology, Vancouver Hospital & Health Sciences Centre Vancouver, Canada

Correspondence to: Dr C. Toze Division of Hematology, Vancouver Hospital & Health Sciences Centre 950 West 10th Avenue Vancouver, BC V5Z 4E3 Canada

Background: Allogeneic bone marrow transplantation (BMT) has been used in patients with low-grade lymphoma (LGL) and chronic lymphocytic leukemia (CLL) with the goal of achieving long-term disease-free survival.

Patients and methods: Twenty-nine patients with these diagnoses (LGL=19, CLL=10) received allogeneic BMT between September 1995 and January 1999. Median age was 42 (range 20–52) years. Twenty-three of twenty-nine patients (79%) were Ann Arbor or Rai stage IV at the time of transplant; twenty-four (83%) had never achieved complete remission (CR). Donor source was HLA-matched sibling (20), unrelated (8) and syngeneic (1).

Results: Seventeen patients are currently alive, a median of 29 months (range 1–85) post-BMT with a median KPS of 90%. Twenty-three of twenty-seven evaluable patients (85%) achieved CR post-BMT. Six patients had refractory/recurrent disease. Death occurred related to transplant complications in eight patients and underlying disease in four. Overall and event-free survival for the whole group is 51% and 44%, respectively.

Conclusions: Allogeneic BMT for young patients with advanced stage LGL or CLL is a feasible strategy that can result in achievement of long-term disease-free survival.

allogeneic bone marrow transplantation, indolent lymphoid neoplasms


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.